Status:
COMPLETED
Comparison of Subacromial Ozone (O2-O3) and Corticosteroid Injections in the Treatment of Rotator Cuff Tendinopathy
Lead Sponsor:
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Conditions:
Rotator Cuff Tendinopathy
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Shoulder pain accounts for approximately 16% of all musculoskeletal symptoms. Rotator cuff tendinopathy is the most common cause of shoulder pain. The aim of this study is to compare the effects of u...
Detailed Description
Shoulder pain accounts for approximately 16% of all musculoskeletal symptoms. Rotator cuff tendinopathy is the most common cause of shoulder pain. There are limited studies comparing the efficacy of ...
Eligibility Criteria
Inclusion
- aged between 18 and 70 years
- pain in the shoulder region and increase in pain with overhead-throwing activity
- chronic shoulder pain for more than 3 months
- partial rotator cuff tear or rotator cuff tendinosis diagnosed by US or magnetic resonance imaging (MRI).
Exclusion
- a full-thickness rotator cuff tear diagnosed by US or MRI
- allergic reaction betamethasone or lidocaine
- contraindications for ozone (O2-O3) injection, such as uncontrolled hyperthyroidism, glucose-6 phosphate dehydrogenase deficiency (G6PDD), pregnancy and platelet level \<50 103/µL
- history of coagulopathy, diabetes, or hepatitis
- intra-articular/subacromial injections in the last 3 months
- history of shoulder infection, fracture, trauma, bony lesion, tumor or inflammatory rheumatic diseases
- history of brachial plexus lesion/cervical radiculopathy.
Key Trial Info
Start Date :
January 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2022
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT05207384
Start Date
January 27 2022
End Date
May 20 2022
Last Update
June 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Merve Örücü Atar
Ankara, Cankaya, Turkey (Türkiye), 06100